We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Results Confirm Effectiveness of Echotherapy for Breast Fibroadenoma

By MedImaging International staff writers
Posted on 21 Jun 2016
Print article
Image: The Ecopulse medical device for the treatment of BFAs and benign thyroid nodules (Photo courtesy of Theraclion).
Image: The Ecopulse medical device for the treatment of BFAs and benign thyroid nodules (Photo courtesy of Theraclion).
A French therapeutic ultrasound company has announced the results of a German trial of its ecotherapy technology that have confirmed its effectiveness in the destruction of Breast FibroAdenoma nodules.

The results of the Breast FibroAdenoma (BFA) trial in which 27 patients were enrolled, were presented at the German Congress of Senology in Dresden, Germany, at the end of May 2016. The aim of the study was to evaluate the safety and efficacy of the new technique.

The trial took place at Tübingen University (Tübingen, Germany). The researchers used therapeutic ultrasound technology developed by Theraclion (Malakoff, France).

Biopsies were performed 12 months after the ecotherapy procedure and showed that nearly 24 of the 27 patients (nearly 90%) had no residual vital BFA tissue. All the patients except for one were prepared to recommend the procedure. The original aim of the non-invasive BFA treatment was to reduce the volume of BFAs, however the new trial confirmed that complete tissue destruction was also possible. The procedure does not using ionizing radiation, and could be used to treat breast cancer patients in the near future.

CMO of Theraclion, Michel Nuta, said, “These results are extremely encouraging. Echotherapy has initially been designed for volume reduction of a nodule, not for its complete destruction. These preliminary results show that there is reason to believe that by adapting the protocol, complete tissue destruction can be obtained.”

Related Links:
Tübingen University
Theraclion
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
MRI System
uMR 588
Ultrasound System
P25 Elite
New
Ultrasound Needle Guide
Ultra-Pro II

Print article

Channels

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.